Noninvasive imaging of PSMA in prostate tumors with 89Zr-Labeled huJ591 engineered antibody fragments: The faster alternatives

Molecular Pharmaceutics

Volumn 11, Issue 11, 2014, Pages 3965-3973

  Viola Villegas, Nerissa Therese ^a   Sevak, Kuntal K ^a   Carlin, Sean D ^a   Doran, Michael G ^a   Evans, Henry W ^a   Bartlett, Derek W ^b   Wu, Anna M ^c   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ImaginAb Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cys diabody; HuJ591; Minibody; PET; PSMA

Indexed keywords

CYSTEINE DIABODY ZR 89; HUJ591 ZR 89; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; ZIRCONIUM 89; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; IMMUNOGLOBULIN FRAGMENT; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; ZIRCONIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; DRUG UPTAKE; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE TUMOR; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOLECULAR IMAGING; PATHOLOGY; PROCEDURES; SCINTISCANNING; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IODINE RADIOISOTOPES; MALE; MICE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SINGLE-CHAIN ANTIBODIES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIRCONIUM;

EID: 84965184547     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500164r     Document Type: Article

References (37)

1. Lee, S. T.; Lawrentschuk, N.; Scott, A. M. PET in prostate and bladder tumors. Semin. Nucl. Med. 2012, 42 (4), 231-46.
2. Fox, J. J.; Schoder, H.; Larson, S. M. Molecular imaging of prostate cancer. Curr. Opin. Urol. 2012, 22 (4), 320-7.
3. Sanz, G.; Rioja, J.; Zudaire, J. J.; Berian, J. M.; Richter, J. A. PET and prostate cancer. World J. Urol. 2004, 22 (5), 351-2.
4. Husarik, D. B.; Miralbell, R.; Dubs, M.; John, H.; Giger, O. T.; Gelet, A.; Cservenyak, T.; Hany, T. F. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35 (2), 253-63.
5. Brogsitter, C.; Zophel, K.; Kotzerke, J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2013, 40 (Suppl. 1), S18-27.
6. Dehdashti, F.; Picus, J.; Michalski, J. M.; Dence, C. S.; Siegel, B. A.; Katzenellenbogen, J. A.; Welch, M. J. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2005, 32 (3), 344-50.
7. Beattie, B. J.; Smith-Jones, P. M.; Jhanwar, Y. S.; Schoder, H.; Schmidtlein, C. R.; Morris, M. J.; Zanzonico, P.; Squire, O.; Meirelles, G. S.; Finn, R.; Namavari, M.; Cai, S.; Scher, H. I.; Larson, S. M.; Humm, J. L. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J. Nucl. Med. 2010, 51 (2), 183-92.
8. Larson, S. M.; Morris, M.; Gunther, I.; Beattie, B.; Humm, J. L.; Akhurst, T. A.; Finn, R. D.; Erdi, Y.; Pentlow, K.; Dyke, J.; Squire, O.; Bornmann, W.; McCarthy, T.; Welch, M.; Scher, H. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 2004, 45 (3), 366-73.
9. Troyer, J. K.; Beckett, M. L.; Wright, G. L., Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995, 62 (5), 552-8.
10. Haffner, M. C.; Kronberger, I. E.; Ross, J. S.; Sheehan, C. E.; Zitt, M.; Muhlmann, G.; Ofner, D.; Zelger, B.; Ensinger, C.; Yang, X. J.; Geley, S.; Margreiter, R.; Bander, N. H. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol. 2009, 40 (12), 1754-61.
11. Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Sheehan, C. E.; Vallabhajosula, S.; Goldsmith, S. J.; Ross, J. S.; Bander, N. H. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 2007, 25 (5), 540-7.
12. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3 (1), 81-5.
13. Chang, S. S.; Heston, W. D. The clinical role of prostate-specific membrane antigen (PSMA). Urol. Oncol. 2002, 7 (1), 7-12.
14. Troyer, J. K.; Feng, Q.; Beckett, M. L.; Wright, G. L., Jr. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol. 1995, 1 (1), 29-37.
15. Troyer, J. K.; Beckett, M. L.; Wright, G. L., Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997, 30 (4), 232-42.
16. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997, 57 (17), 3629-34.
17. Deri, M. A.; Zeglis, B. M.; Francesconi, L. C.; Lewis, J. S. PET imaging with (8)(9)Zr: from radiochemistry to the clinic. Nucl. Med. Biol. 2013, 40 (1), 3-14.
18. Wu, A. M.; Yazaki, P. J.; Tsai, S.; Nguyen, K.; Anderson, A. L.; McCarthy, D. W.; Welch, M. J.; Shively, J.E.; Williams, L. E.; Raubitschek, A. A.; Wong, J. Y.; Toyokuni, T.; Phelps, M. E.; Gambhir, S. S. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (15), 8495-500.
19. Olafsen, T.; Cheung, C. W.; Yazaki, P. J.; Li, L.; Sundaresan, G.; Gambhir, S. S.; Sherman, M. A.; Williams, L.E.; Shively, J. E.; Raubitschek, A. A.; Wu, A. M. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng., Des. Sel. 2004, 17 (1), 21-7.
20. Holland, J. P.; Sheh, Y.; Lewis, J. S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 2009, 36 (7), 729-39.
21. Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 1984, 72 (1), 77-89.
22. Holland, J. P.; Divilov, V.; Bander, N. H.; Smith-Jones, P. M.; Larson, S. M.; Lewis, J. S. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med. 2010, 51 (8), 1293-300.
23. Bartlett, R. M.; Beattie, B. J.; Naryanan, M.; Georgi, J. C.; Chen, Q.; Carlin, S. D.; Roble, G.; Zanzonico, P. B.; Gonen, M.; O'Donoghue, J.; Fischer, A.; Humm, J. L. Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. J. Nucl. Med. 2012, 53 (10), 1608-15.
24. Oehler, C.; O'Donoghue, J. A.; Russell, J.; Zanzonico, P.; Lorenzen, S.; Ling, C. C.; Carlin, S. 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J. Nucl. Med. 2011, 52 (3), 437-44.
25. Rajasekaran, A. K.; Anilkumar, G.; Christiansen, J. J. Is prostate-specific membrane antigen a multifunctional protein?. Am. J. Physiol. 2005, 288 (5), C975-81.
26. Rajasekaran, S. A.; Anilkumar, G.; Oshima, E.; Bowie, J. U.; Liu, H.; Heston, W.; Bander, N. H.; Rajasekaran, A. K. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell 2003, 14 (12), 4835-45.
27. Smith-Jones, P. M.; Vallabahajosula, S.; Goldsmith, S. J.; Navarro, V.; Hunter, C. J.; Bastidas, D.; Bander, N. H. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000, 60 (18), 5237-43.
28. McDevitt, M. R.; Barendswaard, E.; Ma, D.; Lai, L.; Curcio, M. J.; Sgouros, G.; Ballangrud, A. M.; Yang, W. H.; Finn, R. D.; Pellegrini, V.; Geerlings, M. W., Jr.; Lee, M.; Brechbiel, M. W.; Bander, N. H.; Cordon-Cardo, C.; Scheinberg, D. A. An alpha-particle emitting antibody ([213 Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000, 60 (21), 6095-100.
29. Kampmeier, F.; Williams, J. D.; Maher, J.; Mullen, G. E.; Blower, P. J. Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Res. 2014, 4 (1), 13.
30. Wiehr, S.; Buhler, P.; Gierschner, D.; Wolf, P.; Rolle, A. M.; Kesenheimer, C.; Pichler, B. J.; Elsasser-Beile, U. Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody. Prostate 2014, 74 (7), 743-55.
31. Frigerio, B.; Fracasso, G.; Luison, E.; Cingarlini, S.; Mortarino, M.; Coliva, A.; Seregni, E.; Bombardieri, E.; Zuccolotto, G.; Rosato, A.; Colombatti, M.; Canevari, S.; Figini, M. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur. J. Cancer 2013, 49 (9), 2223-32.
32. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 2005, 23 (9), 1137-46.
33. Tasch, J.; Gong, M.; Sadelain, M.; Heston, W. D. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol. 2001, 21 (1-3), 249-61.
34. Liu, H.; Rajasekaran, A. K.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.; Rahmati, R.; Bander, N. H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998, 58 (18), 4055-60.
35. Ghosh, A.; Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 2004, 91 (3), 528-39.
36. Blumenthal, R. D.; Sharkey, R. M.; Snyder, D.; Goldenberg, D. M. Reduction by anti-antibody administration of the radiotoxicity associated with 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. J. Natl. Cancer Inst. 1989, 81 (3), 194-9.
37. McCabe, K. E.; Wu, A. M. Positive progress in immuno PET-not just a coincidence. Cancer Biother. Radiopharm. 2010, 25 (3), 253-61.